|Bid||0.2000 x 400000|
|Ask||0.2050 x 1960600|
|Day's range||0.1900 - 0.2000|
|52-week range||0.0850 - 0.3050|
|Beta (5Y monthly)||0.68|
|PE ratio (TTM)||N/A|
|Earnings date||22 Feb 2022 - 28 Feb 2022|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Under the guidance of CEO Steven Yatomi-Clarke, Prescient Therapeutics Limited ( ASX:PTX ) has performed reasonably...
We can readily understand why investors are attracted to unprofitable companies. By way of example, Prescient...
We can readily understand why investors are attracted to unprofitable companies. For example, Prescient Therapeutics...